Recruiting

The Impact of Anxiety/Depression on the Efficacy of Asthma Control Drugs and the Construction of a Predictive Model for the Risk of Acute Asthma Attacks

The goal of this clinical trial is to explore the impact of anxiety/depression on the efficacy of asthma controller medications and to develop a risk prediction model for asthma acute exacerbations in patients with asthma. It will also analyze the association between anxiety/depression severity and asthma severity. The main questions it aims to answer are: Does anxiety/depression affect the therapeutic effect of asthma controller medications (e.g., asthma control level)? Can a reliable risk prediction model for…

I'm interested View official listing
ClinicalTrials.gov IDNCT07679321
PhaseNot Applicable
Enrollment256
SponsorXiangya Hospital of Central South University
Age14 Years and older
SexALL
I'm interested View official listing

Conditions studied

Anxiety/Depression and Asthma

About this study

The goal of this clinical trial is to explore the impact of anxiety/depression on the efficacy of asthma controller medications and to develop a risk prediction model for asthma acute exacerbations in patients with asthma. It will also analyze the association between anxiety/depression severity and asthma severity. The main questions it aims to answer are: Does anxiety/depression affect the therapeutic effect of asthma controller medications (e.g., asthma control level)? Can a reliable risk prediction model for asthma acute exacerbations be established based on anxiety/depression and other relevant factors? Researchers will conduct a prospective observational study to collect and analyze data from participants, without additional interventions beyond standard clinical care, to explore the above research questions. Participants will: Complete baseline assessments, including demographic information collection, medical history review, lung function tests, anxiety/depression evaluations (via GAD-7 and PHQ-9 scales), and provide biological samples (induced sputum, feces, blood) Undergo follow-up visits at 3, 6, 12, 18, and 24 months after baseline Report asthma symptoms, acute exacerbation events, and cooperate with required clinical checkups during follow-up

Interventions

Primary outcomes

Eligibility information

Inclusion Criteria: * Diagnosis of asthma according to the Global Initiative for Asthma (GINA) 2024 criteria. * Male or female patients aged 14 years or older. * Complete clinical data available. * Newly diagnosed asthma or stable asthma. * Receiving asthma controller medication. Exclusion Criteria: * History of major lung diseases other than asthma, congestive heart failure, cor pulmonale, or recent cardiac or thoracic surgery. * Incomplete medical records. * Cognitive impairment or inability to complete psychological scale assessments. * Clinically diagnosed acute or chronic mental disorders, such as bipolar disorder or schizophrenia. * Current use of antidepressant or anti-anxiety medications. * Pregnancy or lactation.

Study locations

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-10-07.